GlassScriptPhysician profile
Susanna Ferguson
NPI 1669922100
$2,401.82
in general payments reported to CMS, 2019-2025
29 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $747 · 2022: $372 · 2023: $690 · 2024: $348 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268 · Entertainment: $15.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,267.58 |
| Entertainment | $15.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $368.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $234.34 | 2021-2025 | Airsupra, Breztri |
| Pfizer INC. | $228.15 | 2021-2025 | |
| Amarin Pharma, INC. | $218.13 | 2021-2022 | |
| Lilly USA, LLC | $207.88 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $205.91 | 2023-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $102.58 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.09 | 2021-2022 | |
| Astellas Pharma US INC | $84.38 | 2023-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $72.67 | 2021-2023 | Keveyis |
| Boston Scientific Corporation | $68.35 | 2023-2024 | Watchman Access System, Vigilant X4 Crt-D |
| Biohaven Pharmaceutical Holding Company LTD. | $64.95 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.84 | 2021-2024 | Jardiance |
| Mannkind Corporation | $46.38 | 2023 | Afrezza |
| Merck Sharp & Dohme LLC | $43.21 | 2021-2025 | Capvaxive, Gardasil 9 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34.55 | 2021 | |
| Axsome Therapeutics, INC. | $33.25 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $32.19 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.52 | 2022 | |
| Inspire Medical Systems, INC. | $28.83 | 2023 | Inspire |
| Mylan Specialty L.P. | $21.95 | 2021 | |
| Viatris Specialty LLC | $19.26 | 2025 | Yupelri |
| Exact Sciences Corporation | $18.52 | 2024 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $18.11 | 2021 | |
| Seqirus USA INC | $17.16 | 2025 | Flucelvax, Fluad |
| Eisai INC. | $17.13 | 2021 | |
| Optos, INC. | $15.59 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Paratek Pharmaceuticals, INC. | $14.43 | 2025 | Nuzyra |
| Glaxosmithkline, LLC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susanna Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.